These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

342 related items for PubMed ID: 8530634

  • 1. In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.
    Maccario M, Procopio M, Grottoli S, Oleandri SE, Razzore P, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1995 Dec; 80(12):3774-8. PubMed ID: 8530634
    [Abstract] [Full Text] [Related]

  • 2. In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.
    Grottoli S, Procopio M, Maccario M, Zini M, Oleandri SE, Tassone F, Valcavi R, Ghigo E.
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2261-5. PubMed ID: 9215304
    [Abstract] [Full Text] [Related]

  • 3. Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.
    Ghigo E, Goffi S, Nicolosi M, Arvat E, Valente F, Mazza E, Ghigo MC, Camanni F.
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1481-5. PubMed ID: 2229304
    [Abstract] [Full Text] [Related]

  • 4. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F, Dieguez C, Casanueva FF.
    J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
    [Abstract] [Full Text] [Related]

  • 5. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.
    Rigamonti AE, Marazzi N, Cella SG, Cattaneo L, Müller EE.
    J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881
    [Abstract] [Full Text] [Related]

  • 6. Modulation of growth hormone-releasing activity of hexarelin in man.
    Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E.
    Neuroendocrinology; 1995 Jan; 61(1):51-6. PubMed ID: 7731498
    [Abstract] [Full Text] [Related]

  • 7. Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome.
    Procopio M, Invitti C, Maccario M, Grottoli S, Cavagnini F, Camanni F, Ghigo E.
    Int J Obes Relat Metab Disord; 1995 Feb; 19(2):108-12. PubMed ID: 7735336
    [Abstract] [Full Text] [Related]

  • 8. Repetitive GHRH administration fails to increase the response to GHRH in obese subjects. Evidence for a somatotrope defect in obesity?
    Ghigo E, Procopio M, Maccario M, Bellone J, Arvat E, Campana S, Boghen MF, Camanni F.
    Horm Metab Res; 1993 Jun; 25(6):305-8. PubMed ID: 8344645
    [Abstract] [Full Text] [Related]

  • 9. Short-term fasting in obesity fails to restore the blunted GH responsiveness to GH-releasing hormone alone or combined with arginine.
    Procopio M, Maccario M, Grottoli S, Oleandri SE, Boffano GM, Camanni F, Ghigo E.
    Clin Endocrinol (Oxf); 1995 Dec; 43(6):665-9. PubMed ID: 8736266
    [Abstract] [Full Text] [Related]

  • 10. Role of the serotonin receptor subtype 5-HT1D on basal and stimulated growth hormone secretion.
    Mota A, Bento A, Peñalva A, Pombo M, Dieguez C.
    J Clin Endocrinol Metab; 1995 Jun; 80(6):1973-7. PubMed ID: 7775648
    [Abstract] [Full Text] [Related]

  • 11. Growth hormone (GH) responses to GH-releasing hormone alone or combined with arginine in patients with adrenal incidentaloma: evidence for enhanced somatostatinergic tone.
    Terzolo M, Bossoni S, Alí A, Doga M, Reimondo G, Milani G, Peretti P, Manelli F, Angeli A, Giustina A.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1310-5. PubMed ID: 10720081
    [Abstract] [Full Text] [Related]

  • 12. Blunted GH response to growth hormone-releasing hormone (GHRH) alone or combined with arginine in non-insulin-dependent diabetes mellitus.
    Martina V, Bruno G, Tagliabue M, Bertaina S, Maccario M, Grottoli S, Procopio M, Ozzello A, Camanni F.
    Horm Metab Res; 1995 Jan; 27(1):26-30. PubMed ID: 7729789
    [Abstract] [Full Text] [Related]

  • 13. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects.
    Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E.
    J Clin Endocrinol Metab; 1994 Nov; 79(5):1440-3. PubMed ID: 7962341
    [Abstract] [Full Text] [Related]

  • 14. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion.
    Alba-Roth J, Müller OA, Schopohl J, von Werder K.
    J Clin Endocrinol Metab; 1988 Dec; 67(6):1186-9. PubMed ID: 2903866
    [Abstract] [Full Text] [Related]

  • 15. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F, Casanueva FF, Dieguez C.
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [Abstract] [Full Text] [Related]

  • 16. Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity.
    Ghigo E, Procopio M, Boffano GM, Arvat E, Valente F, Maccario M, Mazza E, Camanni F.
    Metabolism; 1992 May; 41(5):560-3. PubMed ID: 1588839
    [Abstract] [Full Text] [Related]

  • 17. Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.
    Lee EJ, Nam SY, Kim KR, Lee HC, Cho JH, Nam MS, Song YD, Lim SK, Huh KB.
    J Clin Endocrinol Metab; 1995 Aug; 80(8):2495-8. PubMed ID: 7629249
    [Abstract] [Full Text] [Related]

  • 18. Arginine abolishes the inhibitory effect of glucose on the growth hormone response to growth hormone-releasing hormone in man.
    Ghigo E, Miola C, Aimaretti G, Valente F, Procopio M, Arvat E, Yin-Zhang W, Camanni F.
    Metabolism; 1992 Sep; 41(9):1000-3. PubMed ID: 1355580
    [Abstract] [Full Text] [Related]

  • 19. Acute administration of recombinant human growth hormone inhibits the somatotrope responsiveness to growth hormone-releasing hormone in childhood.
    Bellone J, Aimaretti G, Valetto MR, Bellone S, Baffoni C, Arvat E, Seminara S, Camanni F, Ghigo E.
    Eur J Endocrinol; 1996 Oct; 135(4):421-4. PubMed ID: 8921823
    [Abstract] [Full Text] [Related]

  • 20. Effects of recombinant human insulin-like growth factor I administration on the growth hormone (gh) response to GH-releasing hormone in obesity.
    Maccario M, Tassone F, Gianotti L, Lanfranco F, Grottoli S, Arvat E, Muller EE, Ghigo E.
    J Clin Endocrinol Metab; 2001 Jan; 86(1):167-71. PubMed ID: 11231996
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.